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Abstract
Candida albicans caused 44% of the overall candidemia episodes from 2006 to 2010 in our
university tertiary care hospital. As different antifungal agents are used in therapy and also
immunocompromised patients receive fluconazole prophylaxis in our institution, this study
aimed to perform an antifungal susceptibility surveillance with the C.albicans bloodstream
isolates and to characterize the fluconazole resistance in 2 non-blood C.albicans isolates
by sequencing ERG11 gene. The study included 147 C. albicans bloodstream samples and
2 fluconazole resistant isolates: one from oral cavity (LIF 12560 fluconazole MIC: 8μg/mL)
and one from esophageal cavity (LIF-E10 fluconazole MIC: 64μg/mL) of two different patients
previously treated with oral fluconazole. The in vitro antifungal susceptibility to amphotericin B
(AMB), 5-flucytosine (5FC), fluconazole (FLC), itraconazole (ITC), voriconazole (VRC), cas-
pofungin (CASP) was performed by broth microdilution methodology recommended by the
Clinical and Laboratory Standards Institute documents (M27-A3 and M27-S4, CLSI). All
blood isolates were classified as susceptible according to CLSI guidelines for all evaluated
antifungal agents (MIC range: 0,125–1.00 μg/mL for AMB,0.125–1.00 μg/mL for 5FC,
0.125–0.5 μg/mL for FLC,0.015–0.125 μg/mL for ITC,0.015–0.06 μg/mL for VRC and
0.015–0.125 μg/mL for CASP). In this study, we also amplified and sequenced the ERG11
gene of LIF 12560 and LIF-E10C.albicans isolates. Six mutations encoding distinct amino
acid substitutions were found (E116D, T128K, E266D, A298V, G448V and G464S) and
these mutations were previously described as associated with fluconazole resistance.
Despite the large consumption of antifungals in our institution, resistant blood isolates were
not found over the trial period. Further studies should be conducted, but it may be that the
very prolonged direct contact with the oral antifungal agent administered to the patient from
which was isolated LIF E-10, may have contributed to the development of resistance.
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Introduction
The spectrum of Candida infection is diverse, starting from asymptomatic colonization to oro-
pharyngeal candidiasis (OPC), cutaneous candidiasis and invasive candidiasis–including can-
didemia [1]. The incidence of candidiasis has risen significantly in recent decades, and
bloodstream infections due to Candida spp. have become an important cause of morbidity and
mortality in hospitalized patients [2, 3].
Oropharyngeal and esophageal candidiasis are representative causes of morbidity in HIV-
infected patients [4, 5], being the most frequent opportunistic fungal infection among these
patients [6].
Strains of C.albicans that are colonizing HIV-infected patients (prior to the first episode of
OPC and antifungal therapy) exhibit an increased frequency of phenotypic switching that
increases the proportion of phenotypes in the colonizing population which are resistant to flu-
conazole [5].
The increased incidence of candidemia has been attributed to numerous factors. One
important factor is an ever-expanding of immunocompromised population due to mucosal or
cutaneous barrier disruption [7], defects in the number and function of neutrophils or in cell-
mediated immunity [2], metabolic dysfunction, and extremes of age [7–9].
The term candidemia describes the presence of Candida species in the blood [10] and is the
most common manifestation of invasive candidiasis [11]. Systemic candidiasis often presents
initially as localized infectious symptoms and can spread to other organs through haemato-
genic route [12]. In all cases, the treatment with an antifungal agent is necessary [13].
Several studies [14–16] associated the high mortality rates with candidemia, demonstrating
the direct proportion between high mortality and patients who were not treated with an anti-
fungal drug. Furthermore, appropriate and timely antifungal therapy is crucial to improves
treatment [7, 9, 17]. The introduction of orally active antifungal azole drugs since the 1980s,
particularly fluconazole, was a significant development allowing treatment of systemic fungal
infections without the problem of nephrotoxicity associated with amphotericin B treatment
[18].
The current use of antifungal agents raises concerns about their potential in selecting and
spreading resistant fungal strains or species [19]. Studies have reported an increasing incidence
of infections caused by yeasts that either have acquired resistance or are intrinsically resistant
to the drug in use [19, 20]. One of the acquired resistance mechanisms is the occurrence of
alterations in the affinity of azole derivatives to cytochrome P450 14-α-demethylase (Erg11p
enzyme), and has been described in different post-treatment yeast species, specially C.albicans
[21]. Nucleotide mutations in ERG11 gene result in amino acid substitutions in Erg11p [22–
25] and, consequently, generate affinity alterations due to conformational changes in Erg11p,
affecting the binding of azole derivatives [26].
The antifungal spectrum varies according to fungal species, such as: C.albicans, C.dublinien-
sis and C.tropicalis are normally susceptible to all antifungals used for the treatment of candide-
mia; C.glabrata is less susceptible and C.krusei is intrinsically resistant to fluconazole.
Additionally, C.parapsilosis is less susceptible to the echinocandins [11, 27].
From 2006 to 2010, a retrospective study [28] was conducted in our hospital to verify the
frequency and distribution of Candida species of blood isolates in different medical specialties.
Candida albicans caused 44% of the overall episodes, followed by C.tropicalis (21.7%), C.para-
psilosis (14.4%), C.glabrata (11.2%), and C.krusei (3.5%). (17) At this time, antifungal suscepti-
bility was performed only for non-C. albicans. In addition, two isolates of fluconazole-resistant
C.albicans were detected in non-blood clinical specimens (personal communication). As in our
Hospital, different antifungal agents are use in therapy and also immunocompromised patients
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receive fluconazole prophylaxis, we performed an antifungal susceptibility surveillance with
the C.albicans bloodstream isolates. The aims of this study were to determine the antifungal
surveillance among C.albicans blood isolates, and to characterize the fluconazole resistance in
non-blood C.albicans isolates by sequencing ERG11 gene.
Materials and Methods
The study was conducted in Hospital and Clinics of the University of Campinas, a tertiary-care
university hospital that provides all major medical services as the referral hospital for five mil-
lion inhabitants.
From 2006 to 2010, 147 episodes of candidemia caused by C. albicans were identified. Noso-
comial candidemia was defined according to the Centers for Disease Control and Prevention
(CDC) criteria [28]. Only one episode per patient was included. All blood samples were col-
lected for routine diagnostic exams and only the Candida albicans isolates were evaluated in
this study and no clinical information was collected. For these isolates no ethical approval was
necessary. Isolates LIF 12560 and LIF E-10 are part of Cristiane Kibune Nagasako project and
were obtained respectively from oral cavity and after esophageal cavity brushing. Procedure
was approved by State University of Campinas School of Medical Sciences Ethics Committee
under number CEP 1316/2011 –CAAE 1218.0.146.000–11.
During the period above, defined daily dose (DDD), defined as the assumed average mainte-
nance dose per day for a drug used for its main indication in adults for the following antifungal
drugs were: fluconazole: 0.2 g; voriconazole: 0.4 g; caspofungin: 50 mg, and amphotericin B: 35
mg [28, 29]. The fungal infections prophylaxis protocol established by the Hospital Infection
Control Commission with fluconazole is applied to patients with acute leukemia, myelodyspla-
sia, hematopoietic stem cell recipients, graft versus host treatment and expectation of severe
and prolonged neutropenia. The route of administration may be oral or intravenous.
Two C.albicans clinical isolates from two individual patients were also included in the
study: one was obtained from oral cavity (LIF 12560) and one from esophageal cavity
(LIF-E10). Both patients were treated previously with oral fluconazole. This study was
approved by the Ethics Committee, No.1316/2011 –CAAE 1218.0.146.000–11.
This study also investigated mutations in ERG11 gene in the two clinical isolates of flucona-
zole-resistant C.albicans (LIF-E10 isolate, fluconazole MIC value: 64μg/mL; LIF 12560 isolate,
fluconazole MIC value: 8μg/mL) using PCR amplification and gene sequencing.
Yeast Identification
Blood cultures were performed by automated microbiological systems BacT/ALERT 3D FA
and PF bottles (bioMérieux, Inc. Durham, NC, USA). For identification, the isolates were cul-
tured on Sabouraud dextrose agar (SDA; Difco, Sparks, Maryland, USA) at 35°C for 48-h
before the tests.
All Candida albicans recovered from cultures were identified according to their macromor-
phology on Sabouraud dextrose agar (Difco, Sparks, Maryland, USA), microscopic morphol-
ogy on cornmeal Tween 80 agar, germ tube test and Vitek™ 2 (bioMérieux, France). All isolates
were stored in sterile distilled water [30].
In Vitro Susceptibility Testing
Antifungal susceptibility tests were performed by using the broth microdilution assay accord-
ing to the methodology recommended by the Clinical and Laboratory Standards Institute
(CLSI) documents M27-A3 [31] and M27-S4 [32]. In vitro antifungal susceptibility profiles
drugs were performed using pre-prepared plates (Eiken Chemical Co., Tokyo, Japan). The
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MICs were obtained with the microorganism’s final concentration of 0.5x103 to 2.5x103 cells/
mL after incubation at 35°C during 72-h. The antifungal agents analyzed were amphotericin B
(AMB) (range 0.03–16 μg/mL), 5-flucytosine (5FC) (range 0.125–64 μg/mL), fluconazole
(FLC) (range 0.125–64 μg/mL), itraconazole (ITC) (range 0.015–8 μg/mL), voriconazole
(VRC) (range 0.015–8 μg/mL) and caspofungin (CASP), which was not available on the plate
and was performed separately. CASP (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in
water and diluted in RPMI 1640 (Sigma-Aldrich, St. Louis, MO, USA). CASP dilutions ranged
from0.015–8 μg/mL. MICs were expressed as susceptible, susceptible dose-dependent or
resistant, according to the CLSI recommendations. The MIC for AMB were defined as the low-
est concentration that caused 100% inhibition of growth, and the MICs other antifungal agents
(5FC, FLC, VRC, ITC and CASP) were described as the lowest concentrations that produced
50% reduction in growth as compared to controls. For amphotericin B, isolates inhibited by
<1 μg/mL were considered susceptible. For quality control, Candida parapsilosis ATCC 22019
and Candida krusei ATCC 6258 strains were included each time that a set of isolates was tested.
The MIC50 and MIC90 were defined as MIC values that inhibited 50 and 90% of the isolates,
respectively.
ERG11Gene Sequencing
The ERG11 genes from isolates were amplified by PCR using the following pairs of primers
(Sigma-Aldrich, St. Louis, MO, USA): ERGSec1A (5’-TTAGTGTTTTATTGGATTCCTTGGT
T-3’) with ERGSec1B (5’-TCTCATTTCATCACCAAATAAAGATC-3’), ERGSec2A (5’-ACCA
GAAATTACTATTTTCACTGCTTCA-3’) with ERGSec2B (5’-AAGTCAAATCATTCAAAT
CACCACCT-3’), and ERGSec3A (5’-AGGTGGTGATTTGAATGATTTGACTT-3’) with
ERGSec3B (5’-GAACTATAATCAGGGTCAGGCACTTT-3’). Amplification of the ERG11 gene
was performed according to Xu et al. (25) in a Veriti 96Well Thermal Cycler (Applied Biosystems,
Foster City, CA, USA) in a final volume of 25μL. Each reaction contained 50ng of DNA, 12.5μL of
PCRMaster Mix (Promega, Fitchburg, WI, USA) and 10mM of each primer. The reaction con-
sisted of 5 min of initial denaturation at 94°C, 33 cycles of 1 min denaturation at 94°C, 1 min
annealing at 58°C, 1 min of extension at 72°C, and a final extension of 7 min at 72°C. The PCR
products were analyzed by electrophoresis in a 2% agarose gel at 100V for 30 min. The sequencing
products were compared to the fluconazole-sensible standard C.albicansATCC 90028.
Results
In Vitro Susceptibility Testing
In our study, we obtained all C.albicans blood isolates fitting on CLSI [31, 32] susceptible (S)
range for all drugs, as shown in Table 1.
MICs for LIF-E10 and LIF 12560 isolates are summarized in Table 2.
ERG11Gene Sequencing
Nucleotide sequence analysis of the ERG11 gene of C.albicans LIF-E10 and LIF 12560 isolates
revealed 6 nucleotide mutations encoding six distinct amino acid substitutions (Table 3):
E116D, T128K, E266D, A298V, G448V and G464S, S1 and S2 Figs. As expected, frequent silent
mutations that do not change the protein sequence were identified (data not shown).
Discussion
With the aim of optimizing the treatment of Candida sp. infections, antifungal susceptibility
testing is recognized as a very useful and important tool. In this study, we provided data on
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antifungal susceptibility of C. albicans blood isolates and all of the 143 isolates were susceptible
to all the tested drugs. After the first isolation of Candida from blood culture all the subsequent
isolates, were evaluated for development of resistance with fluconazole discs as a local routine
surveillance protocol (data not included in this study). The longer antifungal treatment period
observed between first and last Candida isolation for these patients was of at most 2 months.
We have no information about whether these patients were classified or not in the group that
received also prophylactic antifungal. In any event, this fact does not appear to be significant.
As reported in previous studies [33–36], we also observed that C. albicans causing blood-
stream infections were susceptible to amphotericin B. Similarly to our data, other authors
referred up to 100% of C.albicans isolated in blood cultures were susceptible to fluconazole
[35–38], itraconazole [39] and voriconazole [36–38]. Caspofungin also showed potent fungi-
cidal activity against C.albicans [37, 40, 41].
In the present study, we examined the mutations in the ERG11 gene of two fluconazole-
resistant C.albicans and we found six amino acid substitutions (E116D, T128K, E266D,
A298V, G448V and G464S) that were reported previously.
The contribution of the G464S mutation in ERG11 to fluconazole resistance, in C.albicans,
has also been investigated [18, 24, 42]. The relationship of the G464S substitution in flucona-
zole resistance was observed by Kelly et al. (1999), studying the functional expression of C.albi-
cans PCR-amplified ERG11. The G448V substitution was described by Chau et al. [43]
resulting in cross-resistance to fluconazole and voriconazole. In the present study, we found
that G464S substitution significantly increased fluconazole MIC, and the G448V substitution is
probably associated with cross-resistance to fluconazole and voriconazole in LIF-E10 isolate.
Sanglard et al. [22] demonstrated that G464S could increase the resistance to fluconazole, itraco-
nazole and voriconazole. Our isolate LIF-E10 showed resistance to fluconazole and voriconazole,
suggesting that G464S substitution correlates with resistance to this azole drugs. The authors also
described T128K, E266D and A298V [44] substitutions as associated with fluconazole resistance.
Reduced affinity between the resistant isolates (LIF-E10 and LIF 12560) and fluconazole
might be occurring due to amino acid substitutions. In summary, all ERG11 point mutations
Table 1. MICs Distribution (μg/mL) of 143Candida albicans bloodstream isolates against amphotericin B, 5-flucytosine, fluconazole, itraconazole,
voriconazole and caspofungin.
MICs Distribution (μg/mL)
0,015 0,03 0,06 0,125 0,25 0,5 1
Antifungal agent n (%)
Amphotericin B - - - 3 (2,1) 76 (53,1) 64 (44,8) -
5-Flucytosine - - - 123 (86) 14 (9,8) 3 (2,1) 3 (2,1)
Fluconazole - - - 51 (35,6) 79 (55,2) 13 (9,2) -
Itraconazole 17 (11,9) 97 (67,8) 29 (20,3) - - - -
Voriconazole 132 (92,3) 9 (6,3) 2 (1,4) - - - -
Caspofungin 35 (24,5) 43 (30,1) 47 (32,9) 18 (12,5) - - -
doi:10.1371/journal.pone.0158126.t001
Table 2. MIC range (μg/mL) of LIF 12560 and LIF-E10 against amphotericin B, 5-flucytosine, fluconazole, itraconazole and voriconazole.
Antifungal drugs LIF 12560 LIF-E10 Susceptible range (S) according to CLSI (μg/mL)
Anphotericin B 0,25 0,25 __
5-Flucytosine <0,125 <0,125 4
Fluconazole 8 (R) 64 (R) 2
Itraconazole 0,125 0,25 (S-DD) 0,125
Voriconazole 0,25 (S-DD) 1 (R) 0,125
doi:10.1371/journal.pone.0158126.t002
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that resulted in amino acid substitutions are possibly conferring resistance to azoles, particu-
larly fluconazole and voriconazole.
According to clinical records, LIF-E10 was isolated from an HIV-positive patient who aban-
doned treatment with antiretroviral and made use of fluconazole at different periods over
almost seven years, prior to the isolation of the resistant microrganism. According to the litera-
ture, resistant Candida albicans reports from oral and esophageal mucosal from HIV-positive
patients is quite common [45, 46]. Kakati et al. [45] also reported C. albicans resistant esopha-
gitis in immunocompetent individuals.
Conclusions
Despite the large consumption of antifungals in therapy and prophylaxis, in our institution,
resistant blood isolates were not found over the trial period. However, the high incidence of
candidemia due to C.albicans represents a therapeutic challenge where the continuous surveil-
lance of the antifungal susceptibility will help to select the appropriate therapy.
The emergence of resistance of C. albicans strains to azoles may become a problem also for
patients with candidiasis, as fluconazole in many countries is the most common antifungal
drug prescribed for oropharyngeal and vulvovaginitis due to Candida.
Further studies should be conducted to prove, but it may be that the very prolonged direct
contact with the oral antifungal agent administered to the patient from which was isolated LIF
E-10 shown in S1 File, may have contributed to the development of resistance.
Fluconazole is a well tolerant antifungal and has high bioavailability and tissue penetration.
However, prolonged periods of treatment with fluconazole can induce to mutations that
express fluconazole resistance causing treatment failures.
Supporting Information
S1 Fig. Candida albicans LIF 12560 nucleotide mutations and amino acid substitutions. A:
A298V amino acid substitution. B: E116D amino acid substitution. C: E266D amino acid sub-
stitution.D: T128K amino acid substitution.
(TIF)
S2 Fig. Candida albicans LIF E-10 nucleotide mutations and amino acid substitutions. A:
G448V amino acid substitution. B: G464S amino acid substitution.
(TIF)
S1 File. Isolates LIF E-10 (A) and LIF 12560 (B) patients data provided to be released.
(DOCX)
S1 Table. Antifungal susceptibility tests (MIC results).
(DOC)
Table 3. Nucleotide mutations and amino acid substitutions.
Isolates Nucleotide position in ERG11 gene Nucleotide mutation Amino acid substitution
LIF 12560 349 GAA!GAT (349A>T) E116D
384 ACA!AAA (384A>C) T128K
799 GAA!GAC (799A>C) E266D
894 GCT!GTT (894 C>T) A298V
LIF E10 1343 GGG!GTG (1343G>T) G448V
1390 GGT!AGT (1390G>A) G464S
doi:10.1371/journal.pone.0158126.t003
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